Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrafy Life SciencesASX:VFY -1.53%4 Debt-to-Equity is 0.01 as of Jun. 2026, which is at its 10-year median of 0.01. GuruFocus rates ASX:VFY with a GF Score™ of 4/100. The stock has 2 warning signs investors should review. Among 2,238 Software companies, Vitrafy Life Sciences ranks better than 99.96% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Vitrafy Life Sciences's Debt-to-Equity or its related term are showing as below:
ASX:VFY'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.01
Current: 0.01
During the past 5 years, the highest Debt-to-Equity Ratio of Vitrafy Life Sciences was 0.01. The lowest was 0.01. And the median was 0.01.
ASX:VFY's Debt-to-Equity is ranked better than 99.96% of 2238
companies
in the Software industry
Industry Median: 0.2
vs ASX:VFY: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Vitrafy Life Sciences Debt-to-Equity Related Terms
Vitrafy Life Sciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Vitrafy Life Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VFY vs MSFT, PLTR, ORCL: Debt-to-Equity Comparison
For the Software - Infrastructure subindustry, Vitrafy Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrafy Life Sciences Debt-to-Equity vs Software Industry
For the Software industry and Technology sector, Vitrafy Life Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Vitrafy Life Sciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrafy Life Sciences (ASX:VFY) has a Debt-to-Equity of 0.01 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vitrafy Life Sciences and its competitors. This is near median its historical median of 0.01. Over the past decade, Vitrafy Life Sciences' Debt-to-Equity has ranged from 0.01 to 0.01. According to the industry distribution chart, Vitrafy Life Sciences ranks #1 out of 2238 companies in the Software industry, placing it in the top 0%.
Is Vitrafy Life Sciences' Debt-to-Equity too high?
Vitrafy Life Sciences' current Debt-to-Equity of 0.01 is near median its 10-year median of 0.01. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.01. The Software industry median Debt-to-Equity is 0.20. Vitrafy Life Sciences' value of 0.01 is 95% below this industry median. Based on the distribution chart, Vitrafy Life Sciences ranks #1 out of 2238 companies in the Software industry, which is in the top quartile — a strong position relative to peers. Overall, Vitrafy Life Sciences has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Vitrafy Life Sciences' Debt-to-Equity compare to MSFT and PLTR?
According to the Software industry distribution chart, Vitrafy Life Sciences ranks #1 out of 2238 companies for Debt-to-Equity. This places Vitrafy Life Sciences in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.20. Vitrafy Life Sciences' value of 0.01 is 95% below this benchmark. Historically, Vitrafy Life Sciences' own Debt-to-Equity has ranged from 0.01 to 0.01 over the past decade. While the company's 10-year median is 0.01 vs. the industry median of 0.20, Vitrafy Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Software company?
The median Debt-to-Equity among Software companies is 0.20, based on 2,238 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrafy Life Sciences's current Debt-to-Equity of 0.01 is 95% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vitrafy Life Sciences and its competitors. For the Software industry, the median Debt-to-Equity is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrafy Life Sciences's current Debt-to-Equity is 0.01, which is near median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrafy Life Sciences stock overvalued right now?
Vitrafy Life Sciences (ASX:VFY) has a current Debt-to-Equity of 0.01. The current Debt-to-Equity is 0.01, which is near median its 10-year median of 0.01 and 95% below the Software industry median of 0.20. Vitrafy Life Sciences' overall GF Score™ is 4/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Vitrafy Life Sciences (ASX:VFY), the current Debt-to-Equity is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitrafy Life Sciences Ltd developed a range of proprietary smart cryopreservation hardware devices and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials. The company devices includes Vitrafy's Smart Cryopreservation Device; Vitrafy's Smart Thawing Device and Vitrafy's Smart Packaging.
4GF Score
Get the complete analysis for ASX:VFY
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VFY has been successfully added to your 
